Circulating MicroRNAs As Diagnostic Biomarkers of Clinical Cognitive Impairment: A Meta-Analysis

Overview

Journal Am J Alzheimers Dis Other Demen

Publisher Sage Publications

Specialty Neurology

Date 2020 Oct 23

PMID 33094634

Citations 8

Authors

Dan Shi

Mengyu Han

Weilin Liu

Jing Tao

Lidian Chen

Affiliations

Soon will be listed here.

Abstract

Background: Minimally invasive diagnostic biomarkers of neurodegenerative diseases such as Alzheimer's disease (AD) facilitate patient selection and cognitive progressive decline monitoring. However, the diagnostic value of circulating microRNAs (miRNAs) for early cognitive impairment and progression to dementia is currently under debate. Thus, this study aimed to assess the diagnostic performance of circulating, cerebrospinal fluid (CSF) and exosomal miRNAs in the detection of clinical cognitive impairment in mild cognitive impairment (MCI), AD, and MCI-AD.

Methods: We searched PubMed, Embase, Web of Science, China National Knowledge Infrastructure (CNKI), VIP Chinese Science and Technology Journals Database (CQVIP), and Chinese Medicine Premier (Wanfang) to identify potentially eligible studies related to noncoding RNAs and cognitive dysfunction biomarkers published before November 2018. The quality assessment of the studies was performed according to the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) checklist. Meta-analysis of the literature data was performed using Stata/MP 14.0 software. The corresponding effects models were selected to calculate the summary sensitivity, specificity, positive and negative likelihood ratios (PLR and NLR), and diagnostic odds ratio (DOR) and to plot the summary receiver operating characteristic curves (SROCs) and calculate the areas under the curves (AUCs).

Results: A total of 18 studies involving 729 patients with AD, 283 patients with MCI, and 15 patients with MCI-AD were pooled. The results revealed that the sensitivity and specificity of miRNAs in the diagnosis of AD were 0.78 and 0.79, respectively, and the area under the summary receiver operating characteristic curve (AUSROC) was 0.90. The sensitivity and specificity of miRNAs in the diagnosis of MCI were 0.89 and 0.85, respectively, and the AUSROC was 0.94. The sensitivity and specificity of microRNAs in the diagnosis of MCI-AD were 0.87 and 0.84, respectively, and the AUSROC was 0.92.

Conclusion: Our study found that miRNAs have certain diagnostic value for cognitive impairment, with high sensitivity and specificity, especially in diagnostics with multiple miRNAs and serum-based miRNA assays.

Citing Articles

Beyond CSF and Neuroimaging Assessment: Evaluating Plasma miR-145-5p as a Potential Biomarker for Mild Cognitive Impairment and Alzheimer's Disease.

Wen Q, Wittens M, Engelborghs S, van Herwijnen M, Tsamou M, Roggen E ACS Chem Neurosci. 2024; 15(5):1042-1054.

PMID: 38407050 PMC: 10921410. DOI: 10.1021/acschemneuro.3c00740.

Association between erythrocyte membrane fatty acids and gut bacteria in obesity-related cognitive dysfunction.

Zhao T, Huang H, Li J, Shen J, Zhou C, Xiao R AMB Express. 2023; 13(1):148.

PMID: 38123761 PMC: 10733235. DOI: 10.1186/s13568-023-01655-3.

Discerning the Prospects of miRNAs as a Multi-Target Therapeutic and Diagnostic for Alzheimer's Disease.

Bhatnagar D, Ladhe S, Kumar D Mol Neurobiol. 2023; 60(10):5954-5974.

PMID: 37386272 DOI: 10.1007/s12035-023-03446-0.

MicroRNA: A Linking between Astrocyte Dysfunction, Mild Cognitive Impairment, and Neurodegenerative Diseases.

Ramirez A, Gil-Jaramillo N, Tapias M, Gonzalez-Giraldo Y, Pinzon A, Puentes-Rozo P Life (Basel). 2022; 12(9).

PMID: 36143475 PMC: 9505027. DOI: 10.3390/life12091439.

The Effects of a Mixture of Cadmium, Lead, and Mercury on Metabolic Syndrome and Its Components, as well as Cognitive Impairment: Genes, MicroRNAs, Transcription Factors, and Sponge Relationships : The Effects of a Mixture of Cadmium, Lead, and....

Nguyen H, Kim M Biol Trace Elem Res. 2022; 201(5):2200-2221.

PMID: 35798913 DOI: 10.1007/s12011-022-03343-y.

References

Deeks J, Macaskill P, Irwig L . The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. J Clin Epidemiol. 2005; 58(9):882-93. DOI: 10.1016/j.jclinepi.2005.01.016. View

Aganzo M, Montojo M, Lopez de Las Hazas M, Martinez-Descals A, Ricote-Vila M, Sanz R . Customized Dietary Intervention Avoids Unintentional Weight Loss and Modulates Circulating miRNAs Footprint in Huntington's Disease. Mol Nutr Food Res. 2018; 62(23):e1800619. DOI: 10.1002/mnfr.201800619. View

Deeks J . Systematic reviews in health care: Systematic reviews of evaluations of diagnostic and screening tests. BMJ. 2001; 323(7305):157-62. PMC: 1120791. DOI: 10.1136/bmj.323.7305.157. View

Macias Islas M, Ciampi E . Assessment and Impact of Cognitive Impairment in Multiple Sclerosis: An Overview. Biomedicines. 2019; 7(1). PMC: 6466345. DOI: 10.3390/biomedicines7010022. View

Xie B, Zhou H, Zhang R, Song M, Yu L, Wang L . Serum miR-206 and miR-132 as Potential Circulating Biomarkers for Mild Cognitive Impairment. J Alzheimers Dis. 2015; 45(3):721-31. DOI: 10.3233/JAD-142847. View

Kandel E . The biology of memory: a forty-year perspective. J Neurosci. 2009; 29(41):12748-56. PMC: 6665299. DOI: 10.1523/JNEUROSCI.3958-09.2009. View

Tan L, Yu J, Tan M, Liu Q, Wang H, Zhang W . Genome-wide serum microRNA expression profiling identifies serum biomarkers for Alzheimer's disease. J Alzheimers Dis. 2014; 40(4):1017-27. DOI: 10.3233/JAD-132144. View

Pfaffl M, Tichopad A, Prgomet C, Neuvians T . Determination of stable housekeeping genes, differentially regulated target genes and sample integrity: BestKeeper--Excel-based tool using pair-wise correlations. Biotechnol Lett. 2004; 26(6):509-15. DOI: 10.1023/b:bile.0000019559.84305.47. View

Satoh J, Kino Y, Niida S . MicroRNA-Seq Data Analysis Pipeline to Identify Blood Biomarkers for Alzheimer's Disease from Public Data. Biomark Insights. 2015; 10:21-31. PMC: 4401249. DOI: 10.4137/BMI.S25132. View

10.

Kumar P, Dezso Z, Mackenzie C, Oestreicher J, Agoulnik S, Byrne M . Circulating miRNA biomarkers for Alzheimer's disease. PLoS One. 2013; 8(7):e69807. PMC: 3726785. DOI: 10.1371/journal.pone.0069807. View

11.

Petersen R, Negash S . Mild cognitive impairment: an overview. CNS Spectr. 2008; 13(1):45-53. DOI: 10.1017/s1092852900016151. View

12.

Wang T, Chen K, Li H, Dong S, Su N, Liu Y . The feasibility of utilizing plasma MiRNA107 and BACE1 messenger RNA gene expression for clinical diagnosis of amnestic mild cognitive impairment. J Clin Psychiatry. 2015; 76(2):135-41. DOI: 10.4088/JCP.13m08812. View

13.

Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A . Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002; 3(7):RESEARCH0034. PMC: 126239. DOI: 10.1186/gb-2002-3-7-research0034. View

14.

Leidinger P, Backes C, Deutscher S, Schmitt K, Mueller S, Frese K . A blood based 12-miRNA signature of Alzheimer disease patients. Genome Biol. 2013; 14(7):R78. PMC: 4053778. DOI: 10.1186/gb-2013-14-7-r78. View

15.

Weber J, Baxter D, Zhang S, Huang D, Huang K, Lee M . The microRNA spectrum in 12 body fluids. Clin Chem. 2010; 56(11):1733-41. PMC: 4846276. DOI: 10.1373/clinchem.2010.147405. View

16.

Lau P, Bossers K, Janky R, Salta E, Sala Frigerio C, Barbash S . Alteration of the microRNA network during the progression of Alzheimer's disease. EMBO Mol Med. 2013; 5(10):1613-34. PMC: 3799583. DOI: 10.1002/emmm.201201974. View

17.

Farias S, Mungas D, Reed B, Harvey D, DeCarli C . Progression of mild cognitive impairment to dementia in clinic- vs community-based cohorts. Arch Neurol. 2009; 66(9):1151-7. PMC: 2863139. DOI: 10.1001/archneurol.2009.106. View

18.

Petersen R . Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004; 256(3):183-94. DOI: 10.1111/j.1365-2796.2004.01388.x. View

19.

Mestdagh P, Hartmann N, Baeriswyl L, Andreasen D, Bernard N, Chen C . Evaluation of quantitative miRNA expression platforms in the microRNA quality control (miRQC) study. Nat Methods. 2014; 11(8):809-15. DOI: 10.1038/nmeth.3014. View

20.

Hara N, Kikuchi M, Miyashita A, Hatsuta H, Saito Y, Kasuga K . Serum microRNA miR-501-3p as a potential biomarker related to the progression of Alzheimer's disease. Acta Neuropathol Commun. 2017; 5(1):10. PMC: 5282710. DOI: 10.1186/s40478-017-0414-z. View